
The First At-Home Cervical Cancer Screening Wand: Does It Replace Uncomfortable Pap Smears?
The Teal Wand received FDA approval in May and is currently available in California. It should be accessible across the US by 2027. If you're interested in this new, more comfortable type of cervical cancer screening option, read on to get all your questions answered.
How to get and use the Teal Wand
"The Teal Wand is a self-collection device in which the collected sample is mailed to a lab to test for high-risk HPV using an FDA-approved Primary HPV test," said Kara Egan, Teal Health's CEO and co-founder.
The Teal Wand requires a prescription, which you can get through Teal Health on getteal.com. First, you fill out a medical eligibility questionnaire, order a screening kit and schedule a 10-minute virtual visit with a Teal provider. (You can see the OBGYNs and nurse practitioners on Teal's team here.) During the appointment, the provider will review your screening history and discuss the process. After the prescription is approved, a kit will be shipped directly to your home.
Collecting your sample at home only takes a few minutes. Print and video instructions can help guide you, and Teal support can answer questions. When you're done, simply package your sample and ship it to a CLIA-certified lab with the materials provided. (CLIA, or Clinical Laboratory Improvement Amendments, are regulations requiring any facility examining human specimens, like tissue, blood and urine, for diagnosis, prevention or treatment purposes, to be certified by the Secretary of the Department of Health and Human Services.)
After the lab processes your sample, a Teal provider reviews the results in accordance with the screening guidelines defined by the American Society for Colposcopy and Cervical Pathology (ASCCP). You'll receive results in your secure Teal portal within about a week after sending your sample. You'll be given the opportunity to virtually connect with a Teal provider to discuss any next steps. If follow-up care is needed, the Teal team will coordinate your referral.
What the Teal Wand tests for
Just like in the clinician's office, your sample is tested for 14 types of high-risk HPV (Human Papillomavirus) that present the highest risk of causing cervical cancer, Egan said.
According to the World Health Organization, 99% of cervical cancer cases are linked to HPV infections. Primary HPV tests are the most sensitive tests recommended by the American Cancer Society and the US Preventive Services Task Force for cervical cancer screening.
According to Teal Health, the Teal Wand uses the Roche cobas Primary HPV test, which is the same test your doctor would use. Teal's national clinical trial also concluded that "self-collection using the Teal Wand is as accurate as going into the clinic where a provider collects the sample using a speculum and tests for HPV." The Teal Wand is simply a different way of collecting the sample.
Teal Health
Who can use the Teal Wand? How often?
There are three types of cervical cancer tests: Primary HPV testing every five years, Pap tests every three years and co-tests that combine both an HPV test with a Pap test every five years.
According to the ASCCP's guidelines, Primary HPV testing through self-collection, which the Teal Wand uses, is suitable for people at average risk for cervical cancer. Teal Health follows the American Cancer Society's guidelines, which recommend HPV testing every five years for people aged 25 to 65 who have an intact cervix.
Note that the US Centers for Disease Control and Prevention (CDC) recommends that people between the ages of 30 and 65 get either an HPV test, a Pap test or both as a co-test. (This is different from the American Cancer Society's recommendation, which starts at age 25 instead of 30.) If you're considered at risk of cervical cancer, the CDC recommends that you start getting Pap tests as early as age 21.
For those over age 65, consult your doctor. You may not need to be screened anymore if you've received normal or negative results from at least three Pap tests or two HPV tests in the past 10 years, or if you've had your cervix removed during a total hysterectomy for noncancerous conditions like fibroids.
Regardless of how, it's important to get screened regularly, even if you've been vaccinated against HPV. If you're not sure which test is right for you, your doctor can help you decide.
Who shouldn't use the Teal Wand?
Egan said that self-collection with the Teal Wand is not currently recommended for:
patients with a history of cancer in the reproductive system
patients with HIV (human immunodeficiency virus)
patients with DES (diethylstilbestrol, a synthetic form of estrogen) exposure
patients with immunosuppression
patients who have had a treatment for cervical precancer, such as LEEP (Loop Electrosurgical Excision Procedure) or cold knife cone
patients who are pregnant or within six weeks of giving birth
Does the Teal Wand replace a Pap smear?
The Teal Wand is not the same as a Pap smear (cervical cytology). Instead of in-office, clinician-collected samples with a speculum, like you'd have with a Pap smear, Primary HPV screening allows for self-collected samples.
Teal describes a Pap smear as being less sensitive compared to HPV testing because it can only detect cell changes once they've happened, a potential sign that cancer is already present. That's why Pap smears are performed more often than Primary HPV testing (every three years versus five years). On its own, a Pap also doesn't test for HPV, which is the primary cause of almost all cervical cancers.
"Universally, a cervical cancer screening is often called a Pap smear, but Pap smear, along with the HPV test, are both types of tests for cervical cancer screening," Egan said. "Screening for HPV using the Teal Wand is an alternative to screening in person."
In other words, once you screen using the Teal Wand, you don't need to do the test again in your doctor's office. However, if your results are abnormal and positive for HPV, you may need to get additional in-person testing, such as a colposcopy or a Pap smear, to check for cell changes. Your Teal provider will advise you accordingly, per medical guidelines, based on the HPV type detected and your screening history.
While Teal Health aims to help people stay up-to-date on cervical cancer screening, it's always recommended to continue yearly in-person preventive care visits.
Teal Health
Teal Wand costs and health insurance
With select insurance companies, the full at-home screening experience with telehealth consults is available for $99. Without insurance, it's $249, but is eligible for HSA/FSA reimbursement.
Teal Health is currently working with the following insurance plans in California: Cigna, Aetna, Anthem Blue Cross, Blue Shield of California and United Healthcare. The company aims to expand its coverage and also provide financial assistance when needed.
When will the Teal Wand be available outside California?
Teal Health is planning to have the Teal Wand available across the US before the end of 2026.
What's the goal with the Teal Wand?
According to Egan, Teal Health is on a mission to improve women's healthcare experiences. Teal Health is also a member of the Cervical Cancer Roundtable, a collaboration between the American Cancer Society and the Biden Cancer Moonshot, a coalition of industry leaders working to eliminate cervical cancer as a public health concern in the US.
"By creating the option for a woman to screen for cervical cancer from the comfort of home and providing telehealth follow-up, Teal can increase access to this life-saving cancer screening, get more women screened and work toward eliminating cervical cancer in the US, as it is the only cancer nearly 100% preventable with proper screening," said Egan.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Salton Sea not to blame for Coachella, Imperial air pollution, study says
For years, millions of dollars have poured into controlling dust that wafts off the exposed lake shoreline of the Salton Sea, hoping to solve a serious air pollution problem in the Coachella and Imperial valleys. But a new report finds that the dusty shoreline is only responsible for a small percentage of the pollution, prompting some researchers to emphasize that cleaner air inside people's homes, workplaces and schools could be more important in addressing the asthma and respiratory disease that plague the area. "My big takeaway is that there's so many different sources that what we really need to do is pivot away from source control to start protecting people where they're exposed,' said Michael Cohen, a senior researcher at the Pacific Institute and lead author of the report. Released Thursday, the report draws on data from local, state and federal agencies and finds that dust from the expanding dry shore of the Salton Sea accounts for less than 1% of total small particle pollution in the region. The Salton Sea Basin, Coachella Valley and Imperial Valley all violate ozone, or smog, limits. When averaged over the year, Imperial Valley and Salton Sea Basin have twice the state limit for larger particles. Recent research also suggests bacteria and hydrogen sulfide as pollutants of concern. The dust particles are made up of agricultural chemicals from miles of lettuce and spinach fields, manure from livestock operations, diesel exhaust, unpaved roads and fine debris from lithium mining. Previous reports from UC Riverside have called the area one of the most impoverished and environmentally deteriorated regions in California. This mix is why state and local agencies have long focused their attention on dust control projects, planting salt-tolerant vegetation and spreading gravel. To date, California has spent some $49 million to put in more than 3,000 acres of dust suppression around the Salton Sea. But pollution is coming from so many places that money may be best spent in other ways, the researchers say. 'It's just much more effective, more cost-effective to switch to exposure control ... because really, at the end of the day, we're trying to protect public health and improve the lives of people," Cohen said. That could mean focusing on distributing filters, weatherizing homes and alerting people when they should stay and avoid exercising outdoors. A 2023 survey by the UCR School of Medicine showed more than one in five children in communities near the Salton Sea have asthma — almost twice the state average. Some 29% of parents surveyed said their child has had wheezing or breath whistling in the past, most in the last 12 months. The Salton Sea's role in the region's air quality is amplified by its geography. As a desert basin bordered by mountains, it can trap pollutants. Since 2018, the Salton Sea no longer gets an inflow of fresh water, only agricultural runoff, so it is evaporating and shrinking while the exposed, dry lake bed area is expanding, feeding clouds of particulate. Wind patterns, including strong gusts that sweep across the lake bed and surrounding farmland, can also kick up fine, toxic particles and carry them into nearby towns — exposing more residents. Some of the communities have identified pesticides, open burning, road dust and farming operations as among their air priorities. The region includes Calipatria, Brawley, Riverside, Palm Desert and Indio as well smaller communities, many of them mostly Latino or Indigenous. It's not that the Salton Sea is ruled out as a health problem. Dr. David Lo, a UC Riverside professor who has focused for years on air pollution in the region, said certain particles can be especially harmful depending on their chemical or biological makeup. 'A tiny amount of toxic material, even if it's infinitesimally small, can still have really major health effects,' Lo said. If policy emphasis were to shift to indoor air quality, that would leave many people unprotected, said Aydee Rodriguez, environmental justice campaign manager for the nonprofit Alianza Coachella Valley. "We've been noticing an uptick … of asthma-related … emergencies, people having nosebleeds, people having migraines, people feeling dizzy, nauseous,' she said. 'My hope is that the people start to get together and start talking to each other," said study author Cohen. "About what the different agencies are doing, where they're investing their money and how they can leverage and optimize those investments in public health.' This story originally appeared in Los Angeles Times.


CNN
10 minutes ago
- CNN
NIH director lays out agency's research and funding priorities in new strategy statement
The director of the US National Institutes of Health outlined on Friday a 'unified strategy' to align the agency's priorities and funding, a move he said was meant to offer clarification following sweeping changes at the agency, including massive budget cuts, grant cancellations and plans for reorganization. In Friday's statement, Dr. Jay Bhattacharya emphasized the need for transparency with the taxpaying American public and an intent to 'honor their trust.' He identified key priorities for the NIH, including chronic disease and nutrition – as per an executive order 'on Gold-Standard Science and the Make America Healthy Again Commission Report' – as well as artificial intelligence, alternative testing models and real-world data platforms. He also noted that the agency is dedicated to supporting research that pursues 'innovative, and sometimes controversial, questions.' NIH funding decisions will reflect these priorities and other 'core principles,' the statement said. 'As stewards of taxpayer funds, NIH must deliver results that matter to the public,' Bhattacharya wrote. 'Through this strategy, we will better leverage the synergistic missions of each NIH Institute and Center to fund the most meritorious science, address urgent health needs, and sustain a robust biomedical research workforce.' More details were shared on certain agency priorities with an intent to 'clarify specific issues that currently require additional guidance,' the statement said, including autism, nutrition, HIV/AIDS, research on racial disparities, transgender care and more. In April, a policy note from the NIH said the agency can pull medical research funding from universities with diversity and inclusion programs. Friday's statement noted that the NIH was 'shifting to solution-oriented approaches in health disparities research.' 'In contrast to research that considers race or ethnicity when scientifically justified […] research based on ideologies that promote differential treatment of people based on race or ethnicity, rely on poorly defined concepts or on unfalsifiable theories, does not follow the principles of gold-standard science,' the statement read. NIH also intends to prioritize research focused on what it called 'more promising avenues of research' for the the health of transgender youth than studies involving treatments such as puberty suppression, hormone therapy or surgery. 'Research that aims to identify and treat the harms these therapies and procedures have potentially caused to minors diagnosed with gender dysphoria, gender identity disorder, or gender incongruence, and how to best address the needs of these individuals so that they may live long, healthy lives is more promising,' the statement said. Multiple priorities emphasize a preference for domestic research, including a new system to manage projects with funding for foreign research institutions and a blueprint for domestic training programs. NIH will also prioritize research that can be replicated or reproduced. 'We are exploring various mechanisms to support scientists focused on replication work, to publish negative findings, and to elevate replication research,' the statement read.
Yahoo
41 minutes ago
- Yahoo
Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis
Wegovy® (semaglutide) injection 2.4 mg is now indicated to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver, in conjunction with a reduced calorie diet and increased physical activity1 The accelerated approval is based on Part 1 of the ESSENCE trial, in which Wegovy® demonstrated a statistically significant improvement in liver fibrosis (liver scarring) with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis compared to placebo1,2 Wegovy® is also indicated, along with a reduced calorie diet and increased physical activity, to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight, and for adults and children aged 12 years and older with obesity, or some adults with overweight who also have weight-related medical problems, to help them lose excess body weight and keep the weight off1 PLAINSBORO, N.J., Aug. 15, 2025 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a new indication for Wegovy® (semaglutide) injection 2.4 mg, making it the first and only glucagon-like peptide-1 receptor agonist (GLP-1 RA) FDA-approved to treat adults with MASH with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver, in conjunction with a reduced calorie diet and increased physical activity.1 This indication is approved based on improvement of MASH and liver scarring (fibrosis). There is an ongoing study to confirm the clinical benefit of Wegovy® in adults with MASH.1 This FDA approval is based on results from the phase 3 ESSENCE trial investigating the effects of once-weekly Wegovy® 2.4 mg injection on liver histology in adults with MASH and moderate to advanced liver fibrosis (stage F2 to F3) at Week 72. The first primary endpoint showed 63% of people treated with Wegovy® 2.4 mg injection (n=534) achieved resolution of steatohepatitis and no worsening of liver fibrosis compared to 34% on placebo (n=266) with a statistically significant difference in response rate vs placebo of 29 (95% CI, 21;36). Additionally, the second primary endpoint showed 37% of people treated with Wegovy® 2.4 mg achieved improvement in liver fibrosis and no worsening of steatohepatitis compared to 22% on placebo with a statistically significant difference in response rate vs placebo of 14 (95% CI, 8;21). A confirmatory secondary endpoint at Week 72 showed 33% of patients treated with Wegovy® 2.4 mg achieved both resolution of steatohepatitis and improvement in liver fibrosis compared to 16% on placebo with a statistically significant difference in response rate vs placebo of 17 (95% CI, 10;23). A total of 83.5% of the patients in the semaglutide group maintained the target dose of 2.4 mg until Week 72.1,2 "Today's decision by the FDA reflects the continued progress in how we understand and treat patients with MASH, bringing us closer to care that meets the needs of people living with this disease," said Arun Sanyal, MD, Director, Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University. "If left untreated, MASH can lead to serious and potentially fatal outcomes. The clinical evidence seen in ESSENCE underscores the promise of this approach to treating adults with MASH with moderate to advanced liver fibrosis." MASH represents a significant health burden in the US, affecting approximately one in 20 people.3 People living with MASH are often asymptomatic or present with nonspecific symptoms in the early stages of the disease, which may result in a delayed diagnosis.4 Left untreated, MASH can progress to serious and even fatal outcomes, such as cirrhosis, liver cancer, and the need for liver transplant.5 Among people who are living with overweight or obesity worldwide, one in three also have MASH.6 "For far too long, this disease has remained unrecognized, undiagnosed, and often untreated, despite impacting so many people," said Dave Moore, executive vice president of US Operations, at Novo Nordisk. "The FDA's conditional approval of Wegovy® for the treatment of adults with noncirrhotic MASH marks a truly pivotal milestone and a significant step forward for the MASH community and those seeking new options. This builds on the expanding body of evidence demonstrating the clinical benefits of semaglutide across a range of chronic conditions including diabetes, obesity, cardiovascular and chronic kidney disease." The FDA initially approved Wegovy® in 2021 with a reduced calorie meal plan and increased physical activity to help adults with obesity, or some adults with excess weight (overweight) who also have weight-related medical problems to lose weight and keep the weight off. The indication was expanded in 2022 to include children aged 12 years and older with obesity. In 2024, Wegovy® was approved to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and either obesity or overweight.1 Today, the FDA has granted accelerated approval for Wegovy® for a new patient population to treat adults with MASH with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. In February 2025, Novo Nordisk also filed for regulatory approval in the EU, followed by regulatory submission in Japan in May 2025. About ESSENCE ESSENCE is a phase 3 trial evaluating the effect of once-weekly subcutaneous semaglutide 2.4 mg in adults with metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis (stage 2 or 3). It is a two-part trial where 1,197 participants were randomized 2:1 to receive semaglutide 2.4 mg or placebo, on top of standard of care for 240 weeks. Lifestyle counseling and management of coexisting diseases were recommended in alignment with guidelines. In Part 1, the primary objective was to demonstrate that treatment with semaglutide 2.4 mg improves liver histology compared with placebo in patients with MASH and fibrosis stage 2 or 3. In Part 2, which is ongoing, the primary objective is to demonstrate that treatment with semaglutide 2.4 mg lowers the risk of liver-related clinical events compared to placebo in adults with MASH and moderate to advanced liver fibrosis at 240 weeks.2,7 About Metabolic Dysfunction-Associated Steatohepatitis (MASH)MASH is a serious form of fatty liver disease, which can be potentially life-threatening if not properly managed.4 Among people who are living with overweight or obesity worldwide, approximately one in three also have MASH.6 Excess fat can build up in the liver, which, over time, can lead to inflammation and significant scarring of the liver.8 People living with MASH are often asymptomatic or present with nonspecific symptoms in the early stages of the disease, which may result in a delayed diagnosis.4 Approximately one in 20 people in the United States are living with MASH.3 The disease progresses to cirrhosis in an estimated 20% of cases.9 MASH is a leading cause of cirrhosis in adults in the US, and MASH-related cirrhosis is the second most common indication for liver transplants in the country.10 What is Wegovy®?WEGOVY® (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity. to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver This indication is approved based on improvement of MASH and liver scarring (fibrosis). There is an ongoing study to confirm the clinical benefit of Wegovy® in adults with MASH. to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight that may help adults and children aged 12 years and older with obesity, or some adults with excess weight (overweight) who also have weight-related medical problems to lose excess body weight and keep the weight off Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines. It is not known if Wegovy® is safe and effective: for the treatment of MASH in children under 18 years to reduce the risk of major cardiovascular events (death, heart attack, or stroke) in children under 18 years for the treatment of long-term weight loss in children under 12 years Important Safety Information What is the most important information I should know about Wegovy®?Wegovy® may cause serious side effects, including: Possible thyroid tumors, including cancer. Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Wegovy® and medicines that work like Wegovy® caused thyroid tumors, including thyroid cancer. It is not known if Wegovy® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people Do not use Wegovy® if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Do not use Wegovy® if: you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) you have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy® Before using Wegovy®, tell your healthcare provider if you have any other medical conditions, including if you: have or have had problems with your pancreas or kidneys have type 2 diabetes and a history of diabetic retinopathy have or have had depression, suicidal thoughts, or mental health issues are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation) are pregnant or plan to become pregnant. Wegovy® may harm your unborn baby. You should stop using Wegovy® 2 months before you plan to become pregnant are breastfeeding or plan to breastfeed. It is not known if Wegovy® passes into your breast milk Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy® may affect the way some medicines work and some medicines may affect the way Wegovy® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows stomach emptying and can affect medicines that need to pass through the stomach quickly. What are the possible side effects of Wegovy®?Wegovy® may cause serious side effects, including: inflammation of your pancreas (pancreatitis). Stop using Wegovy® and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back gallbladder problems. Wegovy® may cause gallbladder problems, including gallstones. Some gallstones may need surgery. Call your healthcare provider if you have symptoms, such as pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stools increased risk of low blood sugar (hypoglycemia), especially those who also take medicines for diabetes such as insulin or sulfonylureas. This can be a serious side effect. Talk to your healthcare provider about how to recognize and treat low blood sugar and check your blood sugar before you start and while you take Wegovy®. Signs and symptoms of low blood sugar may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Wegovy®. Tell your healthcare provider if you have stomach problems that are severe or will not go away serious allergic reactions. Stop using Wegovy® and get medical help right away, if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat change in vision in people with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Wegovy® increased heart rate. Wegovy® can increase your heart rate while you are at rest. Tell your healthcare provider if you feel your heart racing or pounding in your chest and it lasts for several minutes depression or thoughts of suicide. You should pay attention to any mental changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Wegovy® may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Wegovy® before you are scheduled to have surgery or other procedures The most common side effects of Wegovy® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat. Please click HERE for Wegovy® Prescribing Information and Medication Guide. About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at References Wegovy® (semaglutide) injection [package insert]. Plainsboro, NJ: Novo Nordisk Inc. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2089-2099. doi:10.1056/NEJMoa2 413258 Younossi ZM, Mangla KK, Chandramouli AS, et al. Estimating the economic impact of comorbidities in patients with MASH and defining high-cost burden in patients with noncirrhotic MASH. Hepatol Commun. 2024;8(8):e0488. doi:10.1097/HC9.00000 00000000488 Allen AM, Charlton M, Cusi K, et al. Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting. Postgrad Med. 2024;136(3):229-245. doi:10.1080/00325481.2024.2325332 Kugelmas M, Noureddin M, Gunn N, et al. The use of current knowledge and non-invasive testing modalities for predicting at-risk non-alcoholic steatohepatitis and assessing fibrosis. Liver Int. 2023;43(5):964-974. doi:10.1111/liv.15555 Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20-30. doi:10.1016/S2468-1253(22)00317-X Newsome PN, Sanyal AJ, Engebretsen KA, et al. Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the phase 3 ESSENCE trial. Aliment Pharmacol Ther. 2024;60(11-12):1525-1533. doi:10.1111/apt.18331 National Institute of Diabetes and Digestive and Kidney Diseases. Definition & facts of NAFLD & NASH. Accessed June 13, 2025. Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323(16):1619. doi:10.1001/jama.2020.5249 Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi:10.1002/hep.28431 Wegovy® is a registered trademark of Novo Nordisk A/S. Novo Nordisk is a registered trademark of Novo Nordisk A/S. All other trademarks, registered or unregistered, are the property of their respective owners. © 2025 Novo Nordisk All rights reserved. US25SN00042 August 2025 View original content to download multimedia: SOURCE NOVO NORDISK INC. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data